Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2023

11-09-2023 | Prostate Cancer | Urologic Oncology

High-Intensity Focused Ultrasound (Sonablate®) for Prostate Cancer: Preliminary Outcomes in Taiwan

Authors: Mu Yao Tsai, MD, Chih Tai Lin, MD, Ping Hsuan Chiang, MD, Po Hui Chiang, MD, PhD, EMS, Ping Chia Chiang, MD

Published in: Annals of Surgical Oncology | Issue 13/2023

Login to get access

Abstract

Purpose

We reported preliminary outcomes of high-intensity focused ultrasound (HIFU) [Sonablate®] in the combination of transurethral resection of the prostate for localized prostate cancer in Taiwan.

Methods

Seventy-seven patients using Sonablate® HIFU for localized prostate cancer were enrolled in this study from April 2021 to December 2022. Prostate-specific antigen biochemical recurrence, International Index of Erectile Function (IIEF)-5 scores, International Prostate Symptom Score (IPSS), quality of life (QoL) scores, and postoperative complications were recorded during follow-up.

Results

Overall, 19.5% of patients were low-risk, 36.4% were intermediate-risk, and 44.1% were high-risk according to the D’Amico risk classification. The median follow-up was 12.09 ± 5.85 months, and the biochemical-free survival rates for the low-, intermediate-, and high-risk groups were 100% (15/15), 96.4% (27/28), and 79.4% (27/34), respectively. Four patients (5.2%) received salvage radiotherapy and all maintained biochemical-free survival. The mean IPSS and QoL scores before versus after HIFU were 10.4 versus 6.8 (p = 0.003) and 3.2 versus 3.0 (p = 0.096), respectively. There was no statistically significant change in preoperative and postoperative IIEF scores (20.6 vs. 19; p = 0.062) in patients who had an IIEF score of >15 at baseline and received nerve-sparing procedures (subtotal ablation).

Conclusions

The results of Sonablate® HIFU in Taiwan indicated adequate short-term cancer control, excellent potency, and continence preservation. HIFU can achieve improvement of IPSS with low complication rates.
Literature
1.
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
2.
Cooperberg MR, et al. Contemporary trends in low-risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3 Pt 2):S14–9.PubMedPubMedCentral
3.
Ziglioli F, et al. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer: a review. Ann Med Surg (Lond). 2020;56:110–5.CrossRefPubMedPubMedCentral
4.
Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol. 2008;179(6):2207–10; discussion 2210-1.
5.
Bakavicius A, et al. Comprehensive evaluation of focal therapy complications in prostate cancer: a standardized methodology. J Endourol. 2019;33(7):509–15.CrossRefPubMed
6.
7.
Liu YY, Chiang PH. Comparisons of oncological and functional outcomes between primary whole-gland cryoablation and high-intensity focused ultrasound for localized prostate cancer. Ann Surg Oncol. 2016;23(1):328–34.CrossRefPubMed
8.
Chiang PH, Liu YY. Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation, and high-intensity focused ultrasound for localized prostate cancer. Springerplus. 2016;5(1):1905–12.CrossRefPubMedPubMedCentral
9.
Chen PY, Ching PH, Liu YY, et al. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: the important predictors of biochemical recurrence. Int Urol. 2018;25(6):615–20.CrossRef
10.
Wu YT, Chiang PH. Cohort study of high-intensity focused ultrasound in the treatment of localized prostate cancer treatment: medium-term results from a single center. PLoS One. 2020;15(7):e0236026.CrossRefPubMedPubMedCentral
11.
Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? Br J Radiol. 2003;76(909):590–9.
12.
Bozzini G, et al. Focal therapy of prostate cancer: energies and procedures. Urol Oncol. 2013;31(2):155–67.CrossRefPubMed
13.
Susani M, et al. Morphology of tissue destruction induced by focused ultrasound. Eur Urol. 1993;23(Suppl 1):34–8.CrossRefPubMed
14.
Stride EP, Coussios CC. Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng H 2010;224(2):171–91.
15.
Tourinho-Barbosa RR, de la Rosette J, Sanchez-Salas R. Prostate cancer multifocality, the index lesion, and the microenvironment. Curr Opin Urol. 2018;28(6):499–505.CrossRefPubMed
16.
Sogutdelen E, Haberal HB, Guliyev F, et al. Urethral stricture is an unpleasant complication after prostate surgery: a critical review of current literature. J Urol Surg. 2016;3(1):1–6.CrossRef
17.
Crouzet S, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014;65(5):907–14.CrossRefPubMed
18.
Thüroff S, Chaussy C. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol. 2013;190(2):702–10.
19.
Pinthus JH, et al. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int. 2012;110(8):1142–8.CrossRefPubMed
20.
Misraï V, et al. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol. 2008;26(5):481–5.CrossRefPubMed
21.
Blana A, et al. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol. 2008;53(6):1194–201.CrossRefPubMed
22.
Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep. 2003;4(3):248–52.CrossRefPubMed
23.
Netsch C, Pfeiffer D, Gross AJ. Development of bladder outlet obstruction after a single treatment of prostate cancer with high-intensity focused ultrasound: experience with 226 patients. J Endourol. 2010;24(9):1399–403.CrossRefPubMed
24.
25.
26.
Huang YC, Kan CH, Chiang PH, et al. Salvage radiotherapy plus androgen deprivation therapy for high-risk prostate cancer with biochemical failure after high-intensity focused ultrasound as primary treatment. J Clin Med. 2022;11:4450–8.CrossRefPubMedPubMedCentral
27.
28.
29.
30.
Chaussy CG, Thüroff S. High-intensity focused ultrasound for the treatment of prostate cancer: a review. J Endourol. 2017;31(1):S30–7.CrossRefPubMed
Metadata
Title
High-Intensity Focused Ultrasound (Sonablate®) for Prostate Cancer: Preliminary Outcomes in Taiwan
Authors
Mu Yao Tsai, MD
Chih Tai Lin, MD
Ping Hsuan Chiang, MD
Po Hui Chiang, MD, PhD, EMS
Ping Chia Chiang, MD
Publication date
11-09-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14250-4

Other articles of this Issue 13/2023

Annals of Surgical Oncology 13/2023 Go to the issue

Translational Research

Performance of a Nonlinear Magnetic Handheld Probe for Intraoperative Sentinel Lymph Node Detection: A Phantom Study

Global Health Services Research

Missing Data in Patient-Reported Outcomes Research: Utilizing Multiple Imputation to Address an Unavoidable Problem

ASO Author Reflections

ASO Author Reflections: CTCs in Patients with Gallbladder Adenocarcinoma

Breast Oncology

Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial

Thoracic Oncology

Long-Term Outcomes of Selected Patients with IIIA–N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection

ASO Visual Abstract

ASO Visual Abstract: Routine Use of a Standardized, Mastectomy Diagram by Surgeons Improves Accuracy and Timeliness of the Final Pathological Report